nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—CYP2C19—Sorafenib—liver cancer	0.155	0.284	CbGbCtD
Metoprolol—ABCB1—Sorafenib—liver cancer	0.125	0.229	CbGbCtD
Metoprolol—CYP2D6—Sorafenib—liver cancer	0.118	0.216	CbGbCtD
Metoprolol—ABCB1—Doxorubicin—liver cancer	0.0761	0.139	CbGbCtD
Metoprolol—CYP2D6—Doxorubicin—liver cancer	0.0717	0.131	CbGbCtD
Metoprolol—Mood swings—Sorafenib—liver cancer	0.00397	0.00999	CcSEcCtD
Metoprolol—Abdominal pain upper—Sorafenib—liver cancer	0.00383	0.00963	CcSEcCtD
Metoprolol—Breast disorder—Sorafenib—liver cancer	0.00379	0.00953	CcSEcCtD
Metoprolol—Psoriasis—Epirubicin—liver cancer	0.00339	0.00854	CcSEcCtD
Metoprolol—Erectile dysfunction—Sorafenib—liver cancer	0.00334	0.0084	CcSEcCtD
Metoprolol—Pneumonia—Sorafenib—liver cancer	0.00325	0.00818	CcSEcCtD
Metoprolol—Jaundice—Sorafenib—liver cancer	0.00315	0.00792	CcSEcCtD
Metoprolol—Psoriasis—Doxorubicin—liver cancer	0.00314	0.00791	CcSEcCtD
Metoprolol—Hepatobiliary disease—Sorafenib—liver cancer	0.00305	0.00769	CcSEcCtD
Metoprolol—Connective tissue disorder—Sorafenib—liver cancer	0.00285	0.00717	CcSEcCtD
Metoprolol—Tinnitus—Sorafenib—liver cancer	0.0027	0.0068	CcSEcCtD
Metoprolol—Cardiac disorder—Sorafenib—liver cancer	0.00269	0.00677	CcSEcCtD
Metoprolol—Angiopathy—Sorafenib—liver cancer	0.00263	0.00662	CcSEcCtD
Metoprolol—Immune system disorder—Sorafenib—liver cancer	0.00262	0.00659	CcSEcCtD
Metoprolol—Mediastinal disorder—Sorafenib—liver cancer	0.00261	0.00658	CcSEcCtD
Metoprolol—Arrhythmia—Sorafenib—liver cancer	0.00259	0.00652	CcSEcCtD
Metoprolol—Alopecia—Sorafenib—liver cancer	0.00256	0.00645	CcSEcCtD
Metoprolol—Mental disorder—Sorafenib—liver cancer	0.00254	0.00639	CcSEcCtD
Metoprolol—Dysgeusia—Sorafenib—liver cancer	0.00247	0.00622	CcSEcCtD
Metoprolol—Cardiovascular disorder—Epirubicin—liver cancer	0.00243	0.00611	CcSEcCtD
Metoprolol—Muscle spasms—Sorafenib—liver cancer	0.00243	0.00611	CcSEcCtD
Metoprolol—Syncope—Sorafenib—liver cancer	0.00226	0.0057	CcSEcCtD
Metoprolol—Leukopenia—Sorafenib—liver cancer	0.00226	0.00569	CcSEcCtD
Metoprolol—Cardiovascular disorder—Doxorubicin—liver cancer	0.00225	0.00566	CcSEcCtD
Metoprolol—Loss of consciousness—Sorafenib—liver cancer	0.00222	0.00558	CcSEcCtD
Metoprolol—Atrioventricular block—Epirubicin—liver cancer	0.0022	0.00554	CcSEcCtD
Metoprolol—Hypertension—Sorafenib—liver cancer	0.00218	0.00548	CcSEcCtD
Metoprolol—Musculoskeletal pain—Epirubicin—liver cancer	0.00216	0.00544	CcSEcCtD
Metoprolol—Arthralgia—Sorafenib—liver cancer	0.00215	0.00541	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00213	0.00537	CcSEcCtD
Metoprolol—Ventricular tachycardia—Epirubicin—liver cancer	0.00213	0.00537	CcSEcCtD
Metoprolol—Abnormal dreams—Epirubicin—liver cancer	0.00211	0.00531	CcSEcCtD
Metoprolol—Dry mouth—Sorafenib—liver cancer	0.0021	0.00529	CcSEcCtD
Metoprolol—Atrioventricular block—Doxorubicin—liver cancer	0.00203	0.00512	CcSEcCtD
Metoprolol—Shock—Sorafenib—liver cancer	0.00203	0.0051	CcSEcCtD
Metoprolol—Nervous system disorder—Sorafenib—liver cancer	0.00202	0.00508	CcSEcCtD
Metoprolol—Thrombocytopenia—Sorafenib—liver cancer	0.00202	0.00508	CcSEcCtD
Metoprolol—Skin disorder—Sorafenib—liver cancer	0.002	0.00504	CcSEcCtD
Metoprolol—Musculoskeletal pain—Doxorubicin—liver cancer	0.002	0.00503	CcSEcCtD
Metoprolol—Ventricular tachycardia—Doxorubicin—liver cancer	0.00197	0.00497	CcSEcCtD
Metoprolol—Dry eye—Epirubicin—liver cancer	0.00197	0.00496	CcSEcCtD
Metoprolol—Abnormal dreams—Doxorubicin—liver cancer	0.00195	0.00491	CcSEcCtD
Metoprolol—Coma—Epirubicin—liver cancer	0.00195	0.00491	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00188	0.00472	CcSEcCtD
Metoprolol—Mental disability—Epirubicin—liver cancer	0.00185	0.00466	CcSEcCtD
Metoprolol—Dyspnoea—Sorafenib—liver cancer	0.00184	0.00462	CcSEcCtD
Metoprolol—Dry eye—Doxorubicin—liver cancer	0.00182	0.00459	CcSEcCtD
Metoprolol—Dyspepsia—Sorafenib—liver cancer	0.00181	0.00456	CcSEcCtD
Metoprolol—Coma—Doxorubicin—liver cancer	0.0018	0.00454	CcSEcCtD
Metoprolol—Diabetes mellitus—Epirubicin—liver cancer	0.00178	0.00448	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Sorafenib—liver cancer	0.00178	0.00448	CcSEcCtD
Metoprolol—Fatigue—Sorafenib—liver cancer	0.00178	0.00447	CcSEcCtD
Metoprolol—Hepatic function abnormal—Epirubicin—liver cancer	0.00177	0.00446	CcSEcCtD
Metoprolol—Photosensitivity—Epirubicin—liver cancer	0.00176	0.00444	CcSEcCtD
Metoprolol—Constipation—Sorafenib—liver cancer	0.00176	0.00443	CcSEcCtD
Metoprolol—Pain—Sorafenib—liver cancer	0.00176	0.00443	CcSEcCtD
Metoprolol—Mental disability—Doxorubicin—liver cancer	0.00171	0.00431	CcSEcCtD
Metoprolol—Cardiac failure congestive—Epirubicin—liver cancer	0.00171	0.0043	CcSEcCtD
Metoprolol—Gastrointestinal pain—Sorafenib—liver cancer	0.00168	0.00424	CcSEcCtD
Metoprolol—Hot flush—Epirubicin—liver cancer	0.00166	0.00417	CcSEcCtD
Metoprolol—Diabetes mellitus—Doxorubicin—liver cancer	0.00165	0.00415	CcSEcCtD
Metoprolol—Menopausal symptoms—Epirubicin—liver cancer	0.00164	0.00413	CcSEcCtD
Metoprolol—Hepatic function abnormal—Doxorubicin—liver cancer	0.00164	0.00413	CcSEcCtD
Metoprolol—Urticaria—Sorafenib—liver cancer	0.00164	0.00412	CcSEcCtD
Metoprolol—Photosensitivity—Doxorubicin—liver cancer	0.00163	0.00411	CcSEcCtD
Metoprolol—Abdominal pain—Sorafenib—liver cancer	0.00163	0.0041	CcSEcCtD
Metoprolol—Body temperature increased—Sorafenib—liver cancer	0.00163	0.0041	CcSEcCtD
Metoprolol—Hypoglycaemia—Epirubicin—liver cancer	0.00159	0.00399	CcSEcCtD
Metoprolol—Cardiac failure—Epirubicin—liver cancer	0.00159	0.00399	CcSEcCtD
Metoprolol—Cerebrovascular accident—Epirubicin—liver cancer	0.00158	0.00398	CcSEcCtD
Metoprolol—Cardiac failure congestive—Doxorubicin—liver cancer	0.00158	0.00398	CcSEcCtD
Metoprolol—Hot flush—Doxorubicin—liver cancer	0.00153	0.00386	CcSEcCtD
Metoprolol—Affect lability—Epirubicin—liver cancer	0.00152	0.00384	CcSEcCtD
Metoprolol—Menopausal symptoms—Doxorubicin—liver cancer	0.00152	0.00382	CcSEcCtD
Metoprolol—Hypersensitivity—Sorafenib—liver cancer	0.00152	0.00382	CcSEcCtD
Metoprolol—Asthenia—Sorafenib—liver cancer	0.00148	0.00372	CcSEcCtD
Metoprolol—Cardiac arrest—Epirubicin—liver cancer	0.00147	0.00371	CcSEcCtD
Metoprolol—Hypoglycaemia—Doxorubicin—liver cancer	0.00147	0.0037	CcSEcCtD
Metoprolol—Cardiac failure—Doxorubicin—liver cancer	0.00147	0.0037	CcSEcCtD
Metoprolol—Mood swings—Epirubicin—liver cancer	0.00147	0.00369	CcSEcCtD
Metoprolol—Cerebrovascular accident—Doxorubicin—liver cancer	0.00146	0.00368	CcSEcCtD
Metoprolol—Pruritus—Sorafenib—liver cancer	0.00146	0.00367	CcSEcCtD
Metoprolol—Liver function test abnormal—Epirubicin—liver cancer	0.00143	0.0036	CcSEcCtD
Metoprolol—Abdominal pain upper—Epirubicin—liver cancer	0.00141	0.00356	CcSEcCtD
Metoprolol—Orthostatic hypotension—Epirubicin—liver cancer	0.00141	0.00356	CcSEcCtD
Metoprolol—Affect lability—Doxorubicin—liver cancer	0.00141	0.00355	CcSEcCtD
Metoprolol—Diarrhoea—Sorafenib—liver cancer	0.00141	0.00355	CcSEcCtD
Metoprolol—Breast disorder—Epirubicin—liver cancer	0.0014	0.00352	CcSEcCtD
Metoprolol—Cardiac arrest—Doxorubicin—liver cancer	0.00136	0.00343	CcSEcCtD
Metoprolol—Dizziness—Sorafenib—liver cancer	0.00136	0.00343	CcSEcCtD
Metoprolol—Mood swings—Doxorubicin—liver cancer	0.00136	0.00342	CcSEcCtD
Metoprolol—Liver function test abnormal—Doxorubicin—liver cancer	0.00132	0.00333	CcSEcCtD
Metoprolol—Vomiting—Sorafenib—liver cancer	0.00131	0.0033	CcSEcCtD
Metoprolol—Orthostatic hypotension—Doxorubicin—liver cancer	0.00131	0.00329	CcSEcCtD
Metoprolol—Abdominal pain upper—Doxorubicin—liver cancer	0.00131	0.00329	CcSEcCtD
Metoprolol—Angina pectoris—Epirubicin—liver cancer	0.0013	0.00328	CcSEcCtD
Metoprolol—Rash—Sorafenib—liver cancer	0.0013	0.00327	CcSEcCtD
Metoprolol—Dermatitis—Sorafenib—liver cancer	0.0013	0.00327	CcSEcCtD
Metoprolol—Breast disorder—Doxorubicin—liver cancer	0.00129	0.00326	CcSEcCtD
Metoprolol—Headache—Sorafenib—liver cancer	0.00129	0.00325	CcSEcCtD
Metoprolol—Nausea—Sorafenib—liver cancer	0.00122	0.00308	CcSEcCtD
Metoprolol—Photosensitivity reaction—Epirubicin—liver cancer	0.00122	0.00308	CcSEcCtD
Metoprolol—Weight increased—Epirubicin—liver cancer	0.00122	0.00307	CcSEcCtD
Metoprolol—Angina pectoris—Doxorubicin—liver cancer	0.00121	0.00304	CcSEcCtD
Metoprolol—Pneumonia—Epirubicin—liver cancer	0.0012	0.00302	CcSEcCtD
Metoprolol—Jaundice—Epirubicin—liver cancer	0.00116	0.00293	CcSEcCtD
Metoprolol—Conjunctivitis—Epirubicin—liver cancer	0.00116	0.00292	CcSEcCtD
Metoprolol—Sweating—Epirubicin—liver cancer	0.00114	0.00288	CcSEcCtD
Metoprolol—Photosensitivity reaction—Doxorubicin—liver cancer	0.00113	0.00285	CcSEcCtD
Metoprolol—Hepatobiliary disease—Epirubicin—liver cancer	0.00113	0.00284	CcSEcCtD
Metoprolol—Weight increased—Doxorubicin—liver cancer	0.00113	0.00284	CcSEcCtD
Metoprolol—Agranulocytosis—Epirubicin—liver cancer	0.00111	0.0028	CcSEcCtD
Metoprolol—Pneumonia—Doxorubicin—liver cancer	0.00111	0.0028	CcSEcCtD
Metoprolol—Bradycardia—Epirubicin—liver cancer	0.00109	0.00275	CcSEcCtD
Metoprolol—Jaundice—Doxorubicin—liver cancer	0.00108	0.00271	CcSEcCtD
Metoprolol—Rhinitis—Epirubicin—liver cancer	0.00107	0.0027	CcSEcCtD
Metoprolol—Conjunctivitis—Doxorubicin—liver cancer	0.00107	0.0027	CcSEcCtD
Metoprolol—Hepatitis—Epirubicin—liver cancer	0.00107	0.0027	CcSEcCtD
Metoprolol—Sweating—Doxorubicin—liver cancer	0.00106	0.00266	CcSEcCtD
Metoprolol—Oedema peripheral—Epirubicin—liver cancer	0.00106	0.00266	CcSEcCtD
Metoprolol—Connective tissue disorder—Epirubicin—liver cancer	0.00105	0.00265	CcSEcCtD
Metoprolol—Hepatobiliary disease—Doxorubicin—liver cancer	0.00104	0.00263	CcSEcCtD
Metoprolol—Visual impairment—Epirubicin—liver cancer	0.00103	0.0026	CcSEcCtD
Metoprolol—Agranulocytosis—Doxorubicin—liver cancer	0.00103	0.00259	CcSEcCtD
Metoprolol—Bradycardia—Doxorubicin—liver cancer	0.00101	0.00254	CcSEcCtD
Metoprolol—Eye disorder—Epirubicin—liver cancer	0.001	0.00252	CcSEcCtD
Metoprolol—Tinnitus—Epirubicin—liver cancer	0.000999	0.00251	CcSEcCtD
Metoprolol—Cardiac disorder—Epirubicin—liver cancer	0.000994	0.0025	CcSEcCtD
Metoprolol—Rhinitis—Doxorubicin—liver cancer	0.000994	0.0025	CcSEcCtD
Metoprolol—Hepatitis—Doxorubicin—liver cancer	0.000991	0.0025	CcSEcCtD
Metoprolol—Oedema peripheral—Doxorubicin—liver cancer	0.000976	0.00246	CcSEcCtD
Metoprolol—Connective tissue disorder—Doxorubicin—liver cancer	0.000974	0.00245	CcSEcCtD
Metoprolol—Angiopathy—Epirubicin—liver cancer	0.000972	0.00245	CcSEcCtD
Metoprolol—Immune system disorder—Epirubicin—liver cancer	0.000968	0.00244	CcSEcCtD
Metoprolol—Mediastinal disorder—Epirubicin—liver cancer	0.000965	0.00243	CcSEcCtD
Metoprolol—Arrhythmia—Epirubicin—liver cancer	0.000957	0.00241	CcSEcCtD
Metoprolol—Visual impairment—Doxorubicin—liver cancer	0.000955	0.0024	CcSEcCtD
Metoprolol—Alopecia—Epirubicin—liver cancer	0.000947	0.00238	CcSEcCtD
Metoprolol—Mental disorder—Epirubicin—liver cancer	0.000938	0.00236	CcSEcCtD
Metoprolol—Eye disorder—Doxorubicin—liver cancer	0.000926	0.00233	CcSEcCtD
Metoprolol—Tinnitus—Doxorubicin—liver cancer	0.000924	0.00233	CcSEcCtD
Metoprolol—Cardiac disorder—Doxorubicin—liver cancer	0.00092	0.00232	CcSEcCtD
Metoprolol—Flatulence—Epirubicin—liver cancer	0.000919	0.00231	CcSEcCtD
Metoprolol—Tension—Epirubicin—liver cancer	0.000915	0.0023	CcSEcCtD
Metoprolol—Dysgeusia—Epirubicin—liver cancer	0.000913	0.0023	CcSEcCtD
Metoprolol—Nervousness—Epirubicin—liver cancer	0.000906	0.00228	CcSEcCtD
Metoprolol—Angiopathy—Doxorubicin—liver cancer	0.000899	0.00226	CcSEcCtD
Metoprolol—Muscle spasms—Epirubicin—liver cancer	0.000896	0.00226	CcSEcCtD
Metoprolol—Immune system disorder—Doxorubicin—liver cancer	0.000895	0.00225	CcSEcCtD
Metoprolol—Mediastinal disorder—Doxorubicin—liver cancer	0.000893	0.00225	CcSEcCtD
Metoprolol—Arrhythmia—Doxorubicin—liver cancer	0.000885	0.00223	CcSEcCtD
Metoprolol—Vision blurred—Epirubicin—liver cancer	0.000879	0.00221	CcSEcCtD
Metoprolol—Alopecia—Doxorubicin—liver cancer	0.000876	0.0022	CcSEcCtD
Metoprolol—Mental disorder—Doxorubicin—liver cancer	0.000868	0.00219	CcSEcCtD
Metoprolol—Flatulence—Doxorubicin—liver cancer	0.00085	0.00214	CcSEcCtD
Metoprolol—Tension—Doxorubicin—liver cancer	0.000847	0.00213	CcSEcCtD
Metoprolol—Dysgeusia—Doxorubicin—liver cancer	0.000845	0.00213	CcSEcCtD
Metoprolol—Nervousness—Doxorubicin—liver cancer	0.000838	0.00211	CcSEcCtD
Metoprolol—Vertigo—Epirubicin—liver cancer	0.000838	0.00211	CcSEcCtD
Metoprolol—Syncope—Epirubicin—liver cancer	0.000836	0.00211	CcSEcCtD
Metoprolol—Leukopenia—Epirubicin—liver cancer	0.000835	0.0021	CcSEcCtD
Metoprolol—Muscle spasms—Doxorubicin—liver cancer	0.000829	0.00209	CcSEcCtD
Metoprolol—Palpitations—Epirubicin—liver cancer	0.000824	0.00207	CcSEcCtD
Metoprolol—Loss of consciousness—Epirubicin—liver cancer	0.00082	0.00206	CcSEcCtD
Metoprolol—Vision blurred—Doxorubicin—liver cancer	0.000813	0.00205	CcSEcCtD
Metoprolol—Hypertension—Epirubicin—liver cancer	0.000805	0.00203	CcSEcCtD
Metoprolol—Chest pain—Epirubicin—liver cancer	0.000794	0.002	CcSEcCtD
Metoprolol—Arthralgia—Epirubicin—liver cancer	0.000794	0.002	CcSEcCtD
Metoprolol—Anxiety—Epirubicin—liver cancer	0.000791	0.00199	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000788	0.00198	CcSEcCtD
Metoprolol—Dry mouth—Epirubicin—liver cancer	0.000776	0.00195	CcSEcCtD
Metoprolol—Vertigo—Doxorubicin—liver cancer	0.000775	0.00195	CcSEcCtD
Metoprolol—Syncope—Doxorubicin—liver cancer	0.000774	0.00195	CcSEcCtD
Metoprolol—Leukopenia—Doxorubicin—liver cancer	0.000772	0.00194	CcSEcCtD
Metoprolol—Confusional state—Epirubicin—liver cancer	0.000767	0.00193	CcSEcCtD
Metoprolol—Palpitations—Doxorubicin—liver cancer	0.000762	0.00192	CcSEcCtD
Metoprolol—Oedema—Epirubicin—liver cancer	0.000761	0.00192	CcSEcCtD
Metoprolol—Loss of consciousness—Doxorubicin—liver cancer	0.000758	0.00191	CcSEcCtD
Metoprolol—Shock—Epirubicin—liver cancer	0.000749	0.00188	CcSEcCtD
Metoprolol—Nervous system disorder—Epirubicin—liver cancer	0.000746	0.00188	CcSEcCtD
Metoprolol—Thrombocytopenia—Epirubicin—liver cancer	0.000745	0.00188	CcSEcCtD
Metoprolol—Hypertension—Doxorubicin—liver cancer	0.000745	0.00188	CcSEcCtD
Metoprolol—Tachycardia—Epirubicin—liver cancer	0.000743	0.00187	CcSEcCtD
Metoprolol—Skin disorder—Epirubicin—liver cancer	0.000739	0.00186	CcSEcCtD
Metoprolol—Hyperhidrosis—Epirubicin—liver cancer	0.000736	0.00185	CcSEcCtD
Metoprolol—Arthralgia—Doxorubicin—liver cancer	0.000735	0.00185	CcSEcCtD
Metoprolol—Chest pain—Doxorubicin—liver cancer	0.000735	0.00185	CcSEcCtD
Metoprolol—Anxiety—Doxorubicin—liver cancer	0.000732	0.00184	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000729	0.00184	CcSEcCtD
Metoprolol—Dry mouth—Doxorubicin—liver cancer	0.000718	0.00181	CcSEcCtD
Metoprolol—Hypotension—Epirubicin—liver cancer	0.000711	0.00179	CcSEcCtD
Metoprolol—Confusional state—Doxorubicin—liver cancer	0.00071	0.00179	CcSEcCtD
Metoprolol—Oedema—Doxorubicin—liver cancer	0.000704	0.00177	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000693	0.00175	CcSEcCtD
Metoprolol—Shock—Doxorubicin—liver cancer	0.000693	0.00174	CcSEcCtD
Metoprolol—Nervous system disorder—Doxorubicin—liver cancer	0.000691	0.00174	CcSEcCtD
Metoprolol—Thrombocytopenia—Doxorubicin—liver cancer	0.000689	0.00174	CcSEcCtD
Metoprolol—Insomnia—Epirubicin—liver cancer	0.000688	0.00173	CcSEcCtD
Metoprolol—Tachycardia—Doxorubicin—liver cancer	0.000687	0.00173	CcSEcCtD
Metoprolol—Skin disorder—Doxorubicin—liver cancer	0.000684	0.00172	CcSEcCtD
Metoprolol—Paraesthesia—Epirubicin—liver cancer	0.000683	0.00172	CcSEcCtD
Metoprolol—Hyperhidrosis—Doxorubicin—liver cancer	0.000681	0.00171	CcSEcCtD
Metoprolol—Dyspnoea—Epirubicin—liver cancer	0.000678	0.00171	CcSEcCtD
Metoprolol—Somnolence—Epirubicin—liver cancer	0.000677	0.0017	CcSEcCtD
Metoprolol—Dyspepsia—Epirubicin—liver cancer	0.00067	0.00169	CcSEcCtD
Metoprolol—Hypotension—Doxorubicin—liver cancer	0.000658	0.00166	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Epirubicin—liver cancer	0.000657	0.00165	CcSEcCtD
Metoprolol—Fatigue—Epirubicin—liver cancer	0.000656	0.00165	CcSEcCtD
Metoprolol—Pain—Epirubicin—liver cancer	0.000651	0.00164	CcSEcCtD
Metoprolol—Constipation—Epirubicin—liver cancer	0.000651	0.00164	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000642	0.00162	CcSEcCtD
Metoprolol—Insomnia—Doxorubicin—liver cancer	0.000637	0.0016	CcSEcCtD
Metoprolol—Paraesthesia—Doxorubicin—liver cancer	0.000632	0.00159	CcSEcCtD
Metoprolol—Dyspnoea—Doxorubicin—liver cancer	0.000628	0.00158	CcSEcCtD
Metoprolol—Feeling abnormal—Epirubicin—liver cancer	0.000627	0.00158	CcSEcCtD
Metoprolol—Somnolence—Doxorubicin—liver cancer	0.000626	0.00158	CcSEcCtD
Metoprolol—Gastrointestinal pain—Epirubicin—liver cancer	0.000622	0.00157	CcSEcCtD
Metoprolol—Dyspepsia—Doxorubicin—liver cancer	0.00062	0.00156	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000608	0.00153	CcSEcCtD
Metoprolol—Fatigue—Doxorubicin—liver cancer	0.000607	0.00153	CcSEcCtD
Metoprolol—Urticaria—Epirubicin—liver cancer	0.000605	0.00152	CcSEcCtD
Metoprolol—Constipation—Doxorubicin—liver cancer	0.000602	0.00152	CcSEcCtD
Metoprolol—Pain—Doxorubicin—liver cancer	0.000602	0.00152	CcSEcCtD
Metoprolol—Abdominal pain—Epirubicin—liver cancer	0.000602	0.00151	CcSEcCtD
Metoprolol—Body temperature increased—Epirubicin—liver cancer	0.000602	0.00151	CcSEcCtD
Metoprolol—Feeling abnormal—Doxorubicin—liver cancer	0.00058	0.00146	CcSEcCtD
Metoprolol—Gastrointestinal pain—Doxorubicin—liver cancer	0.000576	0.00145	CcSEcCtD
Metoprolol—Hypersensitivity—Epirubicin—liver cancer	0.000561	0.00141	CcSEcCtD
Metoprolol—Urticaria—Doxorubicin—liver cancer	0.000559	0.00141	CcSEcCtD
Metoprolol—Abdominal pain—Doxorubicin—liver cancer	0.000557	0.0014	CcSEcCtD
Metoprolol—Body temperature increased—Doxorubicin—liver cancer	0.000557	0.0014	CcSEcCtD
Metoprolol—Asthenia—Epirubicin—liver cancer	0.000546	0.00137	CcSEcCtD
Metoprolol—Pruritus—Epirubicin—liver cancer	0.000538	0.00136	CcSEcCtD
Metoprolol—Diarrhoea—Epirubicin—liver cancer	0.000521	0.00131	CcSEcCtD
Metoprolol—Hypersensitivity—Doxorubicin—liver cancer	0.000519	0.00131	CcSEcCtD
Metoprolol—Asthenia—Doxorubicin—liver cancer	0.000505	0.00127	CcSEcCtD
Metoprolol—Dizziness—Epirubicin—liver cancer	0.000503	0.00127	CcSEcCtD
Metoprolol—Pruritus—Doxorubicin—liver cancer	0.000498	0.00125	CcSEcCtD
Metoprolol—Vomiting—Epirubicin—liver cancer	0.000484	0.00122	CcSEcCtD
Metoprolol—Diarrhoea—Doxorubicin—liver cancer	0.000482	0.00121	CcSEcCtD
Metoprolol—Rash—Epirubicin—liver cancer	0.00048	0.00121	CcSEcCtD
Metoprolol—Dermatitis—Epirubicin—liver cancer	0.000479	0.00121	CcSEcCtD
Metoprolol—Headache—Epirubicin—liver cancer	0.000477	0.0012	CcSEcCtD
Metoprolol—Dizziness—Doxorubicin—liver cancer	0.000466	0.00117	CcSEcCtD
Metoprolol—Nausea—Epirubicin—liver cancer	0.000452	0.00114	CcSEcCtD
Metoprolol—Vomiting—Doxorubicin—liver cancer	0.000448	0.00113	CcSEcCtD
Metoprolol—Rash—Doxorubicin—liver cancer	0.000444	0.00112	CcSEcCtD
Metoprolol—Dermatitis—Doxorubicin—liver cancer	0.000444	0.00112	CcSEcCtD
Metoprolol—Headache—Doxorubicin—liver cancer	0.000441	0.00111	CcSEcCtD
Metoprolol—Nausea—Doxorubicin—liver cancer	0.000418	0.00105	CcSEcCtD
Metoprolol—ADRB2—Signaling by GPCR—CSF2—liver cancer	4.09e-05	0.00073	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	4.02e-05	0.000717	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CPT1B—liver cancer	4e-05	0.000714	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GLUL—liver cancer	4e-05	0.000714	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GOT2—liver cancer	3.99e-05	0.000712	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—ALB—liver cancer	3.91e-05	0.000698	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CPT1B—liver cancer	3.9e-05	0.000697	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GLUL—liver cancer	3.9e-05	0.000697	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NR1H4—liver cancer	3.86e-05	0.000688	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ADAM17—liver cancer	3.83e-05	0.000684	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTA3—liver cancer	3.79e-05	0.000677	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NR1H4—liver cancer	3.76e-05	0.000672	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYP2E1—liver cancer	3.75e-05	0.00067	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ADAM17—liver cancer	3.75e-05	0.00067	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	3.71e-05	0.000662	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTA3—liver cancer	3.7e-05	0.00066	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CPT1B—liver cancer	3.68e-05	0.000656	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GLUL—liver cancer	3.68e-05	0.000656	CbGpPWpGaD
Metoprolol—SLC22A2—Neuronal System—HRAS—liver cancer	3.62e-05	0.000647	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—F2—liver cancer	3.61e-05	0.000645	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PSMA4—liver cancer	3.61e-05	0.000644	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PSMD10—liver cancer	3.61e-05	0.000644	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	3.56e-05	0.000635	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NR1H4—liver cancer	3.55e-05	0.000633	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—RAF1—liver cancer	3.54e-05	0.000632	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—F2—liver cancer	3.54e-05	0.000631	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PSMD10—liver cancer	3.53e-05	0.00063	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PSMA4—liver cancer	3.53e-05	0.00063	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYCS—liver cancer	3.51e-05	0.000627	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTA3—liver cancer	3.49e-05	0.000622	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTA4—liver cancer	3.47e-05	0.000619	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CG—liver cancer	3.46e-05	0.000617	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GOT1—liver cancer	3.45e-05	0.000615	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GGT1—liver cancer	3.45e-05	0.000615	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	3.41e-05	0.000609	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	3.4e-05	0.000608	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.39e-05	0.000605	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CG—liver cancer	3.38e-05	0.000604	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTA4—liver cancer	3.38e-05	0.000604	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTA2—liver cancer	3.38e-05	0.000603	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTA2—liver cancer	3.3e-05	0.000589	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—F2—liver cancer	3.28e-05	0.000586	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTA1—liver cancer	3.26e-05	0.000582	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—NAT2—liver cancer	3.22e-05	0.000575	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—F2—liver cancer	3.21e-05	0.000573	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTA4—liver cancer	3.19e-05	0.000569	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTA1—liver cancer	3.18e-05	0.000568	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	3.18e-05	0.000568	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	3.15e-05	0.000563	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—NAT2—liver cancer	3.15e-05	0.000562	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CG—liver cancer	3.14e-05	0.000561	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTA2—liver cancer	3.11e-05	0.000555	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.1e-05	0.000553	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTP1—liver cancer	3.09e-05	0.000552	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALDOB—liver cancer	3.09e-05	0.000552	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CG—liver cancer	3.07e-05	0.000549	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—HMOX1—liver cancer	3.05e-05	0.000545	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CD—liver cancer	3.04e-05	0.000543	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALDOB—liver cancer	3.02e-05	0.000538	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTA1—liver cancer	3e-05	0.000535	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CD—liver cancer	2.97e-05	0.000531	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—NAT2—liver cancer	2.96e-05	0.000529	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CRABP1—liver cancer	2.95e-05	0.000526	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	2.9e-05	0.000517	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CRABP1—liver cancer	2.88e-05	0.000514	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	2.88e-05	0.000513	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GSTM1—liver cancer	2.84e-05	0.000508	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALDOB—liver cancer	2.84e-05	0.000507	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	2.8e-05	0.0005	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PRKCE—liver cancer	2.79e-05	0.000499	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CD—liver cancer	2.76e-05	0.000493	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PRKCE—liver cancer	2.73e-05	0.000488	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CRABP1—liver cancer	2.71e-05	0.000484	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CD—liver cancer	2.7e-05	0.000482	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CYP1A1—liver cancer	2.7e-05	0.000481	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.65e-05	0.000474	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CB—liver cancer	2.65e-05	0.000473	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IGF2—liver cancer	2.65e-05	0.000472	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CB—liver cancer	2.59e-05	0.000463	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IGF2—liver cancer	2.59e-05	0.000462	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—HPGDS—liver cancer	2.58e-05	0.00046	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.56e-05	0.000457	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—HPGDS—liver cancer	2.51e-05	0.000449	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—MTHFR—liver cancer	2.51e-05	0.000449	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CSF2—liver cancer	2.47e-05	0.000441	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PPARA—liver cancer	2.47e-05	0.00044	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—RAF1—liver cancer	2.47e-05	0.00044	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—H2AFX—liver cancer	2.44e-05	0.000435	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—IL2—liver cancer	2.43e-05	0.000435	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CSF2—liver cancer	2.42e-05	0.000431	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—RAF1—liver cancer	2.41e-05	0.00043	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CB—liver cancer	2.41e-05	0.00043	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—H2AFX—liver cancer	2.38e-05	0.000425	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—IL2—liver cancer	2.38e-05	0.000425	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—HPGDS—liver cancer	2.37e-05	0.000423	CbGpPWpGaD
Metoprolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	2.37e-05	0.000423	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CB—liver cancer	2.35e-05	0.00042	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.33e-05	0.000416	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.3e-05	0.000411	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PSMA4—liver cancer	2.3e-05	0.00041	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PSMD10—liver cancer	2.3e-05	0.00041	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PSMA4—liver cancer	2.24e-05	0.0004	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PSMD10—liver cancer	2.24e-05	0.0004	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GOT2—liver cancer	2.23e-05	0.000399	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—IL2—liver cancer	2.21e-05	0.000395	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TERT—liver cancer	2.2e-05	0.000393	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GOT2—liver cancer	2.18e-05	0.000389	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—IL2—liver cancer	2.16e-05	0.000386	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TERT—liver cancer	2.15e-05	0.000385	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	2.14e-05	0.000382	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PSMA4—liver cancer	2.11e-05	0.000377	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PSMD10—liver cancer	2.11e-05	0.000377	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CG—liver cancer	2.11e-05	0.000377	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP2E1—liver cancer	2.1e-05	0.000375	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GOT2—liver cancer	2.05e-05	0.000367	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP2E1—liver cancer	2.05e-05	0.000366	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PPARG—liver cancer	2.04e-05	0.000364	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.03e-05	0.000363	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KDR—liver cancer	2.01e-05	0.00036	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK14—liver cancer	2e-05	0.000357	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KDR—liver cancer	1.97e-05	0.000352	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYCS—liver cancer	1.97e-05	0.000351	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ESR1—liver cancer	1.96e-05	0.00035	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK14—liver cancer	1.96e-05	0.000349	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—F2—liver cancer	1.94e-05	0.000346	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.93e-05	0.000345	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP2E1—liver cancer	1.93e-05	0.000345	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GOT1—liver cancer	1.93e-05	0.000344	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GGT1—liver cancer	1.93e-05	0.000344	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ESR1—liver cancer	1.92e-05	0.000343	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYCS—liver cancer	1.92e-05	0.000342	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—F2—liver cancer	1.9e-05	0.000339	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GGT1—liver cancer	1.88e-05	0.000336	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GOT1—liver cancer	1.88e-05	0.000336	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CD—liver cancer	1.86e-05	0.000331	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CG—liver cancer	1.86e-05	0.000331	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—APC—liver cancer	1.86e-05	0.000331	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—ALB—liver cancer	1.83e-05	0.000327	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—APC—liver cancer	1.82e-05	0.000324	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CG—liver cancer	1.82e-05	0.000324	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYCS—liver cancer	1.81e-05	0.000323	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GGT1—liver cancer	1.77e-05	0.000317	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GOT1—liver cancer	1.77e-05	0.000317	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—BRAF—liver cancer	1.74e-05	0.000311	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTP1—liver cancer	1.73e-05	0.000309	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—HMOX1—liver cancer	1.71e-05	0.000305	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—BRAF—liver cancer	1.71e-05	0.000305	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTP1—liver cancer	1.69e-05	0.000302	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—HMOX1—liver cancer	1.67e-05	0.000298	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CD—liver cancer	1.63e-05	0.000291	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CB—liver cancer	1.62e-05	0.000289	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PIK3CA—liver cancer	1.62e-05	0.000288	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SERPINE1—liver cancer	1.61e-05	0.000288	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—KRAS—liver cancer	1.6e-05	0.000285	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CD—liver cancer	1.6e-05	0.000285	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTP1—liver cancer	1.59e-05	0.000284	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GSTM1—liver cancer	1.59e-05	0.000284	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PIK3CA—liver cancer	1.58e-05	0.000282	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SERPINE1—liver cancer	1.58e-05	0.000282	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—HMOX1—liver cancer	1.57e-05	0.00028	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—KRAS—liver cancer	1.56e-05	0.000279	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GSTM1—liver cancer	1.55e-05	0.000277	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CYP1A1—liver cancer	1.51e-05	0.000269	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CYP1A1—liver cancer	1.47e-05	0.000263	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PIK3CA—liver cancer	1.47e-05	0.000262	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GSTM1—liver cancer	1.46e-05	0.000261	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—RAF1—liver cancer	1.46e-05	0.00026	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PIK3CA—liver cancer	1.44e-05	0.000256	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—RAF1—liver cancer	1.42e-05	0.000254	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MTOR—liver cancer	1.42e-05	0.000254	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CB—liver cancer	1.42e-05	0.000254	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—MTHFR—liver cancer	1.41e-05	0.000251	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CB—liver cancer	1.39e-05	0.000248	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MTOR—liver cancer	1.39e-05	0.000248	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CYP1A1—liver cancer	1.39e-05	0.000248	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PPARA—liver cancer	1.38e-05	0.000246	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—MTHFR—liver cancer	1.37e-05	0.000245	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—HRAS—liver cancer	1.36e-05	0.000242	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PPARA—liver cancer	1.35e-05	0.00024	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1B—liver cancer	1.33e-05	0.000238	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—HRAS—liver cancer	1.33e-05	0.000237	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—AKT1—liver cancer	1.32e-05	0.000236	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CASP3—liver cancer	1.31e-05	0.000233	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL2—liver cancer	1.31e-05	0.000233	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1B—liver cancer	1.31e-05	0.000233	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—IL6—liver cancer	1.3e-05	0.000232	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—MTHFR—liver cancer	1.29e-05	0.000231	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—AKT1—liver cancer	1.29e-05	0.00023	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CASP3—liver cancer	1.28e-05	0.000228	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL2—liver cancer	1.28e-05	0.000228	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CCND1—liver cancer	1.27e-05	0.000227	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—IL6—liver cancer	1.27e-05	0.000227	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—JUN—liver cancer	1.27e-05	0.000227	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PPARA—liver cancer	1.27e-05	0.000227	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CTNNB1—liver cancer	1.26e-05	0.000225	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CCND1—liver cancer	1.25e-05	0.000222	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—JUN—liver cancer	1.24e-05	0.000222	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.24e-05	0.000221	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MMP9—liver cancer	1.24e-05	0.000221	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CTNNB1—liver cancer	1.23e-05	0.00022	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CDKN1A—liver cancer	1.23e-05	0.00022	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MMP9—liver cancer	1.21e-05	0.000216	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CDKN1A—liver cancer	1.2e-05	0.000215	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MAPK8—liver cancer	1.2e-05	0.000215	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—AKT1—liver cancer	1.2e-05	0.000214	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CG—liver cancer	1.18e-05	0.000211	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MAPK8—liver cancer	1.18e-05	0.00021	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—AKT1—liver cancer	1.17e-05	0.000209	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CG—liver cancer	1.15e-05	0.000206	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PPARG—liver cancer	1.14e-05	0.000204	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PPARG—liver cancer	1.11e-05	0.000199	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—VEGFA—liver cancer	1.11e-05	0.000198	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—STAT3—liver cancer	1.1e-05	0.000196	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CG—liver cancer	1.09e-05	0.000194	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—VEGFA—liver cancer	1.09e-05	0.000194	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—STAT3—liver cancer	1.07e-05	0.000192	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PPARG—liver cancer	1.05e-05	0.000187	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CD—liver cancer	1.04e-05	0.000185	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—ALB—liver cancer	1.03e-05	0.000183	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—MYC—liver cancer	1.02e-05	0.000182	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TGFB1—liver cancer	1.02e-05	0.000182	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CD—liver cancer	1.01e-05	0.000181	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—ALB—liver cancer	1e-05	0.000179	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—MYC—liver cancer	9.99e-06	0.000178	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TGFB1—liver cancer	9.96e-06	0.000178	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—PIK3CA—liver cancer	9.86e-06	0.000176	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CD—liver cancer	9.56e-06	0.000171	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—KRAS—liver cancer	9.43e-06	0.000168	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—ALB—liver cancer	9.43e-06	0.000168	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—KRAS—liver cancer	9.23e-06	0.000165	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CB—liver cancer	9.06e-06	0.000162	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CB—liver cancer	8.84e-06	0.000158	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PIK3CA—liver cancer	8.67e-06	0.000155	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PIK3CA—liver cancer	8.48e-06	0.000151	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—TP53—liver cancer	8.38e-06	0.00015	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CB—liver cancer	8.33e-06	0.000149	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—TP53—liver cancer	8.2e-06	0.000146	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—AKT1—liver cancer	8.06e-06	0.000144	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—HRAS—liver cancer	8.02e-06	0.000143	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—HRAS—liver cancer	7.84e-06	0.00014	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—IL6—liver cancer	7.67e-06	0.000137	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—IL6—liver cancer	7.51e-06	0.000134	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—AKT1—liver cancer	7.08e-06	0.000126	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—AKT1—liver cancer	6.93e-06	0.000124	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—PIK3CA—liver cancer	5.52e-06	9.86e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—PIK3CA—liver cancer	5.39e-06	9.62e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—PIK3CA—liver cancer	5.08e-06	9.06e-05	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—AKT1—liver cancer	4.51e-06	8.05e-05	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—AKT1—liver cancer	4.4e-06	7.86e-05	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—AKT1—liver cancer	4.15e-06	7.41e-05	CbGpPWpGaD
